MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ocugen

< Previous 1 2 3 4 5 Next >
News headline image
Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Business Advisory Board
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present at BIO International Convention 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Provides Business Update with First Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present at Retinal Vascular Disease Drug Development Summit
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Appoints Quan A. Vu as Chief Business Officer
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Provides Business Update & Third Quarter 2022 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
From Ocugen
Via GlobeNewswire
Tickers OCGN
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story